Valuation : Fortress Biotech, Inc.

Market Cap 90.71M 78.06M 73.44M 67.09M 126M 8.56B 126M 868M 337M 4.39B 341M 333M 14.16B P/E 2026 *
1.07x
P/E 2027 * -2.72x
Enterprise Value 90.71M 78.06M 73.44M 67.09M 126M 8.56B 126M 868M 337M 4.39B 341M 333M 14.16B EV / Sales 2026 *
1.15x
EV / Sales 2027 * 0.8x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day+0.37%
1 week-1.81%
Current month-0.55%
1 month-1.81%
3 months+2.64%
6 months-18.56%
Current year-25.68%
1 week 2.63
Extreme 2.63
2.77
1 month 2.57
Extreme 2.57
3.06
Current year 2.18
Extreme 2.18
4.53
1 year 2.18
Extreme 2.18
4.53
3 years 1.24
Extreme 1.24
6.15
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap. Importance
1/4/26 Free

Chief Financial Officer

2,967 0.0096%
18/3/26 Free

Chief Executive Officer

475,424 1.5318%
18/3/26 Free

Director

475,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
+0.37%-1.81%-26.68%-53.49% 90.71M
-1.87%+4.22%+44.36%+1.14% 82.65B
-0.76%+0.50%-17.24%-36.14% 60.24B
-2.23%+5.48%+478.96%+34.47% 58.11B
+1.31%-1.35%-7.43%+30.97% 49.68B
-0.19%-2.37%-0.10%+153.74% 46.66B
-1.64%+1.07%+56.98%-16.26% 32.63B
-0.98%+1.91%+46.30%+100.59% 25.69B
-1.07%-5.77%-1.75%+191.93% 22.73B
-0.88%+0.31%+63.48%+105.28% 16.54B
Average -0.79%-0.13%+63.69%+51.22% 39.5B
Weighted average by Cap. -0.99%+0.95%+86.43%+42.49%

Financials

2026 *2027 *
Net sales 78.79M 67.8M 63.79M 58.27M 109M 7.44B 109M 754M 293M 3.82B 296M 289M 12.3B 113M 97.45M 91.69M 83.76M 157M 10.69B 157M 1.08B 420M 5.49B 425M 416M 17.67B
Net income 88.25M 75.94M 71.45M 65.27M 122M 8.33B 122M 844M 328M 4.27B 331M 324M 13.77B -37.81M -32.54M -30.61M -27.97M -52.32M -3.57B -52.46M -362M -140M -1.83B -142M -139M -5.9B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
04/09/26 USD 2.720 +0.37% 168,144
03/09/26 USD 2.710 -0.73% 148,109
02/09/26 USD 2.730 +1.87% 279,774
01/09/26 USD 2.680 -2.01% 605,780
31/08/26 USD 2.735 -1.26% 326,337
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.720USD
Average target price
11.00USD
Spread / Average Target
+304.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!